15/04/2008 (Agence Europe) - In a press release issued on 14 April, the European Medicines Agency (EMEA) said that the Committee for Orphan Medicinal Products had recommended that eight medicines be designated orphan medicinal products for the treatment of (1) thrombotic thrombocytopenic purpura, (2) congenital alpha-1 antitrypsin deficiency, (3) multiple myeloma, (4) malignant mesothelioma, (5) pancreatic cancer, (6) haemophilia A, (7) haemophilia B, and (8) glioma. More information is...